Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.46 |
| ▸ | CTSA | P10619 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636441 | 0.93 | EGLN2 (0.49) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15636502 | 0.92 | CYP26A1 (0.48) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15637118 | 0.91 | APLNR (0.45) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15636670 | 0.90 | EGLN2 (0.49) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15636828 | 0.89 | CTSA (0.55) | EGLN2EGLN1CYP26A1CTSASUCNR1 | |
| SCHEMBL15636372 | 0.87 | CTSA (0.47) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15636384 | 0.87 | CTSA (0.53) | EGLN2EGLN1CYP26A1CTSA | |
| SCHEMBL15636524 | 0.87 | CTSA (0.55) | CYP26A1CTSASUCNR1 | |
| SCHEMBL15637241 | 0.87 | CTSA (0.55) | CYP26A1CTSASUCNR1 | |
| SCHEMBL15636722 | 0.86 | CTSA (0.48) | EGLN2EGLN1CYP26A1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014053533-A1 | USE OF SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AS PHARMACEUTICALS FOR PREVENTION/TREATMENT OF ATRIAL FIBRILLATION | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |